NLTX Share Price | Neoleukin Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Neoleukin Therapeutics, Inc.?

Market Cap: As of Jun 18, Neoleukin Therapeutics, Inc. has a market capitalization of 386.45 million, categorized as a Micro Cap.Recent Quarterly Performance: For the latest four quarters, Neoleukin Therapeutics reported net sales of 0.93 million and a net profit of -80.87 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 310.38 million and total assets of 336.44 million.

Q: What does Neoleukin Therapeutics, Inc. do?

Overview:Neoleukin Therapeutics, Inc. is a biopharmaceutical company focused on developing computationally-designed protein therapeutics to address unmet medical needs in immuno-oncology, inflammation, and autoimmunity, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Profit: -23 Million (Quarterly Results - Mar 2025) Market cap: USD 386.45 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.99 Return on Equity: -27.71% Price to Book: 1.32 Contact Details:Address: 1616 Eastlake Ave E Ste 360, SEATTLE WA: 98102-3795 Tel: 1 206 7322133 Website: https://www.neoleukin.com/

Q: Is Neoleukin Therapeutics, Inc. overvalued or undervalued?

As of 1 August 2019, Neoleukin Therapeutics, Inc. has moved from a risky valuation grade to one that does not qualify. The company is currently overvalued, given its significant financial challenges reflected in its ratios. The price-to-book value stands at 1.57, while the EV to EBITDA is a concerning -1.95, indicating that the company is not generating positive earnings before interest, taxes, depreciation, and amortization. Additionally, the return on equity (ROE) is at -27.71%, highlighting the company's struggles in generating profit from shareholders' equity.In comparison to its peers, Neoleukin's valuation metrics are alarming. For instance, CorMedix, Inc. shows a P/E ratio of 55.03, while Poseida Therapeutics, Inc. has a P/E of -15.24, both indicating a stark contrast in performance and valuation. Furthermore, Neoleukin's recent stock performance has lagged significantly behind the S&P 500, with a year-to-date return of -24.67% compared to the index's 2.44%. Overall, the combination of poor financial ratios and underperformance relative to peers suggests that Neoleukin Therapeutics, Inc. is overvalued at its current price of $17.22.

Q: Is Neoleukin Therapeutics, Inc. technically bullish or bearish?

As of 22 August 2025, the technical trend for Neoleukin Therapeutics, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD remains bearish, while the monthly MACD shows a mildly bullish stance. Daily moving averages indicate a mildly bullish trend. However, the weekly Bollinger Bands and KST are bearish, and Dow Theory shows a mixed signal with a mildly bearish weekly and mildly bullish monthly outlook. Overall, the current technical stance is mildly bullish, but the strength is tempered by conflicting indicators.In terms of performance, Neoleukin has underperformed significantly compared to the S&P 500 across all multi-period returns, with a 1Y return of -54.77% versus the S&P 500's 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

59.07 k

Shareholding (Mar 2025)

FII

4.90%

Held by 37 FIIs

DII

67.9%

Held by 18 DIIs

Promoter

11.15%

How big is Neoleukin Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Neoleukin Therapeutics, Inc. has a market capitalization of 386.45 million and reported net sales of 0.93 million with a net profit of -80.87 million over the latest four quarters. The company has shareholder's funds of 310.38 million and total assets of 336.44 million as of Dec 24.

View full answer

What does Neoleukin Therapeutics, Inc. do?

22-Jun-2025

Neoleukin Therapeutics, Inc. is a biopharmaceutical company that develops computationally-designed protein therapeutics for immuno-oncology, inflammation, and autoimmunity. It has a market cap of $386.45 million and reported a net profit loss of $23 million as of March 2025.

View full answer

Who are in the management team of Neoleukin Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Neoleukin Therapeutics, Inc. includes Mr. Todd Simpson (Independent Chairman), Dr. Jonathan Drachman (CEO), and several directors: Mr. Martin Babler, Ms. Erin Lavelle, Ms. M. Cantey Boyd, Dr. Sarah Noonberg, and Dr. Lewis Williams. This team combines executive leadership with independent directors for effective governance.

View full answer

Is Neoleukin Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

Neoleukin Therapeutics, Inc. is currently overvalued at $17.22 due to significant financial challenges, including a price-to-book ratio of 1.57, an EV to EBITDA of -1.95, and a return on equity of -27.71%, all while underperforming compared to its peers and the S&P 500.

View full answer

Is Neoleukin Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 22, 2025, Neoleukin Therapeutics shows a mildly bullish technical trend despite conflicting indicators, while significantly underperforming the S&P 500 with a 1-year return of -54.77% compared to its 17.14%.

View full answer

Compare Neoleukin Therapeutics, Inc. with Similar Stocks

Vigil Neuroscience, Inc.Invivyd, Inc.Foghorn Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 420 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.99

Return on Equity

-30.88%

Price to Book

1.54

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-22 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-3.99%

6 Months

-30.93%

1 Year

-56.17%

2 Years

4.92%

3 Years

-18.96%

4 Years

-92.3%

5 Years

-94.34%

Neoleukin Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-186.08%

EBIT to Interest (avg)

-60.78

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.99

Sales to Capital Employed (avg)

0.00

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

92.47%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.57

EV to EBIT

-1.88

EV to EBITDA

-1.95

EV to Capital Employed

73.99

EV to Sales

168.47

PEG Ratio

Dividend Yield

ROCE (Latest)

-3941.37%

ROE (Latest)

-27.71%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 24 Schemes (16.04%)

Foreign Institutions

Held by 37 Foreign Institutions (4.9%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -100.00% vs 0.00% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -18.92% vs -780.95% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.90",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-25.30",
          "val2": "-19.30",
          "chgp": "-31.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-22.00",
          "val2": "-18.50",
          "chgp": "-18.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-21,766.50%",
          "chgp": "2,176.65%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -106.89% vs 34.24% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.90",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-79.40",
          "val2": "-52.30",
          "chgp": "-51.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-75.10",
          "val2": "-36.30",
          "chgp": "-106.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-89,302.70%",
          "val2": "0.00%",
          "chgp": "-8,930.27%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

0.90

-100.00%

Operating Profit (PBDIT) excl Other Income

-25.30

-19.30

-31.09%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-22.00

-18.50

-18.92%

Operating Profit Margin (Excl OI)

0.00%

-21,766.50%

2,176.65%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is -100.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -18.92% vs -780.95% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.90

0.00

Operating Profit (PBDIT) excl Other Income

-79.40

-52.30

-51.82%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-75.10

-36.30

-106.89%

Operating Profit Margin (Excl OI)

-89,302.70%

0.00%

-8,930.27%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -106.89% vs 34.24% in Dec 2023

All Annual Results

Company CV

About Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Neoleukin Therapeutics, Inc., formerly Aquinox Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is focused on the development and commercialization of computationally-designed protein therapeutics to address unmet medical needs in immuno-oncology, inflammation, and autoimmunity. Its computational platform allows it to design new de novo proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its lead program, NL-201, is a computationally-designed de novo protein therapeutic. NL-201 is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. NL-201 is designed for use as a single-agent or in combination with complementary therapeutic modalities.

Company Coordinates

Company Details

1616 Eastlake Ave E Ste 360 , SEATTLE WA : 98102-3795

Tel: 1 206 7322133

https://www.neoleukin.com/

Registrar Details

Neoleukin Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Neoleukin Therapeutics, Inc.?

Watch in Real-Time

What does Neoleukin Therapeutics, Inc. do?

Who are in the management team of Neoleukin Therapeutics, Inc.?

Is Neoleukin Therapeutics, Inc. overvalued or undervalued?

Is Neoleukin Therapeutics, Inc. technically bullish or bearish?

Compare Neoleukin Therapeutics, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Neoleukin Therapeutics, Inc.

Company Coordinates